Patients participating in a recent Northwestern University study experienced up to a 12.1 percent reduction in body weight after 36 weeks of taking the oral GLP-1 drug aleniglipron. This small-molecule treatment can be taken with or without food and potentially combined with other therapies, according to researchers. The drug is currently in development and has not yet received approval from the Food and Drug Administration (FDA).
How Does Aleniglipron Differ from Current GLP-1 Options?
The primary distinction of aleniglipron lies in its chemical structure. According to Dr. Robert Kushner, a co-author of the Northwestern study, the drug is a “small molecule,” meaning it is chemically made. Because it functions like traditional oral medications such as aspirin or blood pressure treatments, researchers suggest it may offer greater flexibility for patients managing multiple health conditions simultaneously.
The shift toward oral, small-molecule drugs aims to increase patient adherence.
What Do the Clinical Trial Results Show?
Researchers tracked 230 adults with overweight or obesity across 38 U.S. medical centers to measure the efficacy of varying doses. According to the Northwestern study, weight loss results after 36 weeks were dose-dependent:
- 45-milligram group: 9.0 percent average weight loss.
- 90-milligram group: 10.7 percent average weight loss.
- 120-milligram group: 12.1 percent average weight loss.
A separate study conducted by Structure Therapeutics reported results, with participants achieving approximately 16 percent weight loss over a 39-week period.
Are There Known Side Effects or Safety Risks?
Participants in the Northwestern study reported mild to moderate gastrointestinal side effects, which researchers noted tended to decrease over time. Dr. Kushner stated that investigators did not identify any new safety signals or concerns. To further improve tolerability for patients in upcoming phase III trials, researchers plan to implement a slower dose escalation schedule, according to the study findings.
Frequently Asked Questions
Is aleniglipron currently available for prescription?
No. According to the Cleveland Clinic, the drug is still in the development phase and has not yet been approved by the FDA.
Can I take aleniglipron with food?
Yes. Dr. Kushner notes that because aleniglipron is a small-molecule drug, it can be taken with or without food.
How does this compare to injectable GLP-1s?
While the study found aleniglipron stimulates insulin secretion, suppresses appetite and increases satiety, it remains in the testing phase.
Always consult with a licensed medical professional before considering any new weight-loss medication. Clinical trials reflect controlled environments; real-world efficacy and side effects can vary by individual.
Stay informed about the latest developments in medical technology by subscribing to our health newsletter. Have questions about how new obesity treatments work? Join the conversation in the comments section below.
